Gilead Sciences (NASDAQ:GILD) Given New $190.00 Price Target at Wells Fargo & Company

Gilead Sciences (NASDAQ:GILD) had its price objective lifted by Wells Fargo & Company from $165.00 to $190.00 in a research report report published on Friday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biopharmaceutical company’s stock.

Several other equities analysts have also weighed in on GILD. Jefferies Financial Group reaffirmed a “buy” rating and issued a $185.00 price objective on shares of Gilead Sciences in a research note on Friday, October 23rd. Needham & Company LLC set a $175.00 target price on shares of Gilead Sciences in a research report on Friday. UBS Group restated a “buy” rating and issued a $195.00 price target on shares of Gilead Sciences in a report on Friday. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Finally, Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a research report on Friday. Twenty-three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $169.19.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $170.68 on Friday. Gilead Sciences has a twelve month low of $114.02 and a twelve month high of $175.65. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The business’s fifty day moving average price is $150.87 and its 200 day moving average price is $139.79.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. The firm had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative return on equity of 1.70% and a negative net margin of 12.47%. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.47 earnings per share. As a group, equities analysts expect that Gilead Sciences will post -0.48 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a $0.82 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the transaction, the chief financial officer directly owned 161,096 shares of the company’s stock, valued at approximately $25,166,417.12. The trade was a 1.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the transaction, the director directly owned 12,894 shares in the company, valued at $1,916,306.28. This trade represents a 58.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 111,000 shares of company stock worth $15,877,860. Insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in GILD. Covestor Ltd grew its stake in shares of Gilead Sciences by 21.5% during the third quarter. Covestor Ltd now owns 876 shares of the biopharmaceutical company’s stock valued at $131,000 after acquiring an additional 155 shares in the last quarter. Caldwell Trust Co increased its position in shares of Gilead Sciences by 39.3% during the third quarter. Caldwell Trust Co now owns 1,705 shares of the biopharmaceutical company’s stock worth $254,000 after acquiring an additional 481 shares during the last quarter. 3Chopt Investment Partners LLC lifted its stake in shares of Gilead Sciences by 0.8% in the third quarter. 3Chopt Investment Partners LLC now owns 22,751 shares of the biopharmaceutical company’s stock worth $3,391,000 after acquiring an additional 180 shares in the last quarter. Rakuten Investment Management Inc. lifted its stake in shares of Gilead Sciences by 10.4% in the third quarter. Rakuten Investment Management Inc. now owns 330,225 shares of the biopharmaceutical company’s stock worth $49,956,000 after acquiring an additional 31,109 shares in the last quarter. Finally, Provenance Wealth Advisors LLC lifted its stake in shares of Gilead Sciences by 412.3% in the third quarter. Provenance Wealth Advisors LLC now owns 13,418 shares of the biopharmaceutical company’s stock worth $2,000,000 after acquiring an additional 10,799 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.